Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Lung Cancer ; 173: 1-4, 2022 11.
Article in English | MEDLINE | ID: mdl-36099795

ABSTRACT

Here we report the prevalence of incidental findings (IF) in the Manchester Lung Health Check pilot, which delivered mobile low-dose CT targeted lung cancer screening. 187 IFs were reported in 158 participants (11.2 % of individuals screened; n = 1,409). 101 IFs in 90 participants (6.4 %) were concerning for extra-pulmonary malignancy. IFs resulted in 118 imaging studies, 20 invasive investigations, and 106 new diagnoses, including 5 malignancies (0.35 %). Clinical management of IFs required 84 specialist reviews (6.0 %), 34 medication changes (2.4 %) and 10 interventional treatments (0.71 %). Lung cancer screening detects clinically relevant IFs but further research is needed to better understand the potential benefits and harms of such findings to participants.


Subject(s)
Early Detection of Cancer , Lung Neoplasms , Humans , Early Detection of Cancer/methods , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/epidemiology , Incidental Findings , Smokers , Tomography, X-Ray Computed/methods , Lung , Mass Screening/methods
2.
Clin Oncol (R Coll Radiol) ; 34(11): 708-715, 2022 11.
Article in English | MEDLINE | ID: mdl-36175244

ABSTRACT

Lung cancer remains the most significant cause of cancer death, accounting for about 20% of all cancer-related mortality. A significant reason for this is delayed diagnosis, either due to lack of symptoms in early-stage disease or presentation with non-specific symptoms common with a broad range of alternative diagnoses. More is needed in terms of increasing public awareness, providing adequate healthcare professional education and implementing clinical pathways that improve the earlier diagnosis of symptomatic lung cancer. Low-dose computed tomography screening of high-risk, asymptomatic populations has been shown to reduce lung cancer mortality, with focus now shifting towards how best to implement lung cancer screening on a wider scale in a safe, efficient and cost-effective manner. For maximum benefit, efforts must be made to optimise uptake, especially among high-risk populations with significant socioeconomic deprivation, as well as successfully incorporate tobacco-dependency treatment. Quality assured programme management will be critical to minimising screening-related harms and adequately managing incidental findings. By undertaking the above, there can be optimism that lung cancer outcomes can be improved significantly in the near future.


Subject(s)
Early Detection of Cancer , Lung Neoplasms , Cost-Benefit Analysis , Early Detection of Cancer/methods , Humans , Lung Neoplasms/diagnostic imaging , Mass Screening , Tomography, X-Ray Computed/methods
3.
Lung Cancer ; 124: 148-153, 2018 10.
Article in English | MEDLINE | ID: mdl-30268454

ABSTRACT

BACKGROUND: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in populations eligible for lung cancer screening. The aim of this study was to determine whether a brief CV risk assessment, delivered as part of a targeted community-based lung cancer screening programme, was effective in identifying individuals at high risk who might benefit from primary prevention. METHODS: The Manchester Lung Screening Pilot consisted of annual low dose CT (LDCT) over 2 screening rounds, targeted at individuals in deprived areas at high risk of lung cancer (age 55-74 and 6-year risk ≥1.51%, using PLCOM2012 risk model). All participants of the second screening round were eligible to take part in the study. Ten-year CV risk was estimated using QRISK2 in participants without CVD and compared to age (±5 years) and sex matched Health Survey for England (HSE) controls; high risk was defined as QRISK2 score ≥10%. Coronary artery calcification (CAC) was assessed on LDCT scans and compared to QRISK2 score. RESULTS: Seventy-seven percent (n=920/1,194) of screening attendees were included in the analysis; mean age 65.6 ± 5.4 and 50.4% female. QRISK2 and lung cancer risk (PLCOM2012) scores were correlated (r = 0.26, p < 0.001). Median QRISK2 score was 21.1% (IQR 14.9-29.6) in those without established CVD (77.6%, n = 714/920), double that of HSE controls (10.3%, IQR 6.6-16.2; n = 714) (p < 0.001). QRISK2 score was significantly higher in those with CAC (p < 0.001). Screening attendees were 10-fold more likely to be classified high risk (OR 10.2 [95% CI 7.3-14.0]). One third (33.7%, n = 310/920) of all study participants were high risk but not receiving statin therapy for primary CVD prevention. DISCUSSION: Opportunistic CVD risk assessment within a targeted lung cancer screening programme is feasible and is likely to identify a very large number of individuals suitable for primary prevention.


Subject(s)
Cardiovascular Diseases/diagnosis , Early Detection of Cancer/methods , Lung Neoplasms/diagnosis , Aged , Calcinosis , Cardiovascular Diseases/epidemiology , England/epidemiology , Female , Humans , Lung Neoplasms/epidemiology , Male , Middle Aged , Risk , Risk Assessment
4.
Eur Respir J ; 33(1): 171-81, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19118228

ABSTRACT

In addition to direct antibacterial actions, 14- and 15-member-ring macrolides have immune modulating effects that appear to be the reason for clinical benefit in diffuse panbronchiolitis. A literature search was conducted for studies of the clinical effectiveness of macrolides in other chronic lung conditions. A number of studies were identified that showed short-term beneficial outcomes or the potential for such outcomes in cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, asthma and post-transplant obliterative bronchiolitis. The studies were limited by small patient numbers, different outcome measures and short-term follow-up, and were not designed to assess potentially harmful effects. Further large prospective and long-term studies are required in order to identify potential benefit and harm before these agents can be recommended routinely for these conditions.


Subject(s)
Lung Diseases/drug therapy , Lung Diseases/pathology , Macrolides/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Drug Administration Schedule , Humans , Lung Diseases/etiology , Lung Transplantation/adverse effects , Macrolides/adverse effects
5.
Respir Med ; 99(9): 1198-200, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16085225

ABSTRACT

This case describes platypnoea-orthodeoxia syndrome in a patient 2 months after a right pneumonectomy for adenocarcinoma of the lung. The patient complained of platypnoea (breathlessness in the upright position) and was noted to have orthodeoxia (arterial desaturation on standing) on clinical examination. This was due to anatomical changes after the pneumonectomy that resulted in direct blood flow from the inferior vena cava through a previously unrecognised atrial septal defect into the left atrium. The closure of this right to left shunt with an Amplatzer occluder produced immediate and striking symptomatic relief in the patient. The authors had no previous experience of this very rare complication of pneumonectomy. The diagnosis was made after a literature search using PubMed/Medline, underlining the direct clinical benefit provided by these databases.


Subject(s)
Hypoxia/etiology , Pneumonectomy/adverse effects , Adenocarcinoma/surgery , Echocardiography, Transesophageal , Female , Heart Septal Defects, Ventricular/complications , Heart Septal Defects, Ventricular/diagnostic imaging , Humans , Lung Neoplasms/surgery , Middle Aged , Posture , PubMed , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...